Ontario Pension Board

Medicure Inc. is a specialty pharmaceutical company based in Winnipeg, Canada, that focuses on the research, development, and commercialization of cardiovascular therapies primarily for the U.S. hospital market. Established in 1997, Medicure initially dedicated its efforts to research and development but shifted to a commercial focus in 2008. The company markets AGGRASTAT, an injection used to treat acute coronary syndrome, and offers other products including ZYPITAMAG for lipid disorders and ReDS, a non-invasive device for measuring lung fluid in congestive heart failure management. Medicure also provides Sodium Nitroprusside injection for blood pressure regulation and surgical procedures. The company is committed to enhancing patient outcomes while pursuing growth through product development and acquisition opportunities, solidified by the FDA approval of AGGRASTAT's new label in 2013, which has facilitated sales growth and profitability. Medicure’s operational subsidiaries include Medicure International, based in Barbados, which holds U.S. rights to AGGRASTAT, and Medicure USA, involved in product distribution in the U.S.